Regenerex Pharma, Inc. (OTC: RGPX)

Regenerex Pharma Inc specializes in the development and commercialization of advanced wound care healing products. The company operates through three distinct proprietary technologies designed to address different wound care needs: Chronic Wound Closure Technology for closing chronic wounds, Acute Wound Acceleration Technology focused on accelerating closure of acute or surgical wounds, and Contamination Control Technology addressing contamination issues across all wound types, including biofilm destruction. These technologies form the foundation of Regenerex Pharma Inc's product portfolio, which includes the Wound Closure System and protocols treating diabetic ulcers, pressure ulcers, venous ulcers, burns, and surgical wounds.

Regenerex Pharma Inc generates revenue through the sale of its proprietary wound care products, including Xcellderma™ OTC Liquid Bandage Skin Protectant, an over-the-counter sterile wound dressing effective for wounds, skin irritations, cuts, and abrasions, and Accelerex™ Sterile Wound Cream, the first commercially available medical device containing QBx™ designed for treating chronic and acute wounds such as diabetic ulcers, burns, pressure ulcers (stages I-IV), and venous stasis ulcers. Revenue is derived from healthcare sectors including U. S. Government-funded home care service providers, state Medicaid programs, international healthcare programs, Veterans Administration, correctional facility healthcare systems, home health care providers, and Medicare reimbursement programs. The company pursues strategic partnerships with distributors across Asian and Middle Eastern markets and is developing managed care agreements with southeastern state governments to manage Medicaid wound care patients.

The company operates through the following segments: Chronic Wound Closure Technology, Acute Wound Acceleration Technology, and Contamination Control Technology.

• Chronic Wound Closure Technology is specifically designed for closing chronic wounds by addressing underlying protease imbalances that impede healing.

• Acute Wound Acceleration Technology focuses on accelerating closure of acute or surgical wounds through enhanced healing mechanisms.

• Contamination Control Technology addresses contamination issues across all wound types, including biofilm destruction, to create optimal conditions for wound healing.

Regenerex Pharma Inc maintains significant competitive advantages through its proprietary QBx™ technology, which down-regulates specific proteases and matrix metalloproteases (MMPs) known to impede wound healing, with approximately 80% of chronic wounds displaying elevated protease levels. The company's Wound Closure System has demonstrated closure rates of up to 95% of non-responding chronic wounds within 90 days in clinical trials, outperforming conventional treatments. Regenerex Pharma Inc differentiates itself by actively modifying the cellular environment rather than merely providing protective coverage like hydrocolloids or collagen dressings, and no other currently available products successfully heal chronic, non-healing wounds through its proprietary mechanisms of action.

The company serves hospitals, nursing homes, home health providers, wound care clinics, state Medicaid programs, Veterans Administration facilities, correctional healthcare systems, and international healthcare providers in Asian and Middle Eastern markets. Regenerex Pharma Inc targets customers operating under pay-for-performance reimbursement models resulting from the Affordable Care Act, with home health and nursing homes representing the fastest-growing segments due to demographic trends including aging population and increasing rates of diabetes and obesity.